FDA Communication On Missed Deadlines Can Help Avoid Drug Review Limbo
Executive Summary
Providing a new target decision date in tandem with missing a user fee review deadline would help FDA restore credibility and predictability to the review process, former FDA official Bruce Burlington suggests
You may also be interested in...
FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally
FDA is heading into 2009 with at least a dozen missed review deadlines held over from 2008 - potentially setting up the agency and industry for what could be an unusually higher number of drug and biologic approvals this year
FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally
FDA is heading into 2009 with at least a dozen missed review deadlines held over from 2008 - potentially setting up the agency and industry for what could be an unusually higher number of drug and biologic approvals this year
U.S. FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
U.S. FDA has set a new action date of June 26, 2009 for Takeda's dipeptidyl peptidase IV inhibitor alogliptin, after missing the original user fee deadline of Oct. 27, the company announced Dec. 24